
Merck’s $1 billion deal includes phase 3 ovarian cancer therapeutic
Merck (NYSE:MRK) has forged a deal with a biopharmaceutical company for its phase 3 platinum-resistant ovarian cancer treatment and nonsmall cell lung cancer in mid-stage development in a deal valued at up to $1 billion. Under the terms of the deal, Merck, through a subsidiary, will get worldwide rights to develop and commercialize vintafolide for […]